公开(公告)号：US20170260275A1

公开(公告)日：2017-09-14

申请号：US15529594

申请日：2015-12-04

Applicant: Novartis AG

Inventor： Patrick KORTEBEIN ,  Daniel ROOKS ,  Lloyd B. KLICKSTEIN ,  Ronenn ROUBENOFF ,  David GLASS ,  Estelle TRIFILIEFF ,  Dimitris PAPANICOLAOU

IPC: C07K16/28

Abstract: The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age-related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function.